California State Teachers Retirement System boosted its stake in shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) by 10.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 74,633 shares of the company’s stock after buying an additional 7,291 shares during the period. California State Teachers Retirement System owned about 0.17% of Amphastar Pharmaceuticals worth $1,203,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in shares of Amphastar Pharmaceuticals by 49.0% in the second quarter. Bank of New York Mellon Corp now owns 190,849 shares of the company’s stock valued at $3,076,000 after buying an additional 62,731 shares during the period. Kalmar Investments Inc. DE bought a new stake in Amphastar Pharmaceuticals during the second quarter valued at $3,397,000. Essex Investment Management Co. LLC increased its stake in Amphastar Pharmaceuticals by 236.0% in the second quarter. Essex Investment Management Co. LLC now owns 105,239 shares of the company’s stock valued at $1,696,000 after buying an additional 73,922 shares during the last quarter. American Century Companies Inc. bought a new stake in Amphastar Pharmaceuticals during the second quarter valued at $467,000. Finally, Strs Ohio increased its stake in Amphastar Pharmaceuticals by 5.3% in the second quarter. Strs Ohio now owns 47,900 shares of the company’s stock valued at $772,000 after buying an additional 2,400 shares during the last quarter. 35.87% of the stock is owned by institutional investors.
Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) traded up 1.62% during midday trading on Friday, reaching $20.07. 1,593,403 shares of the company’s stock were exchanged. The company has a market capitalization of $905.58 million, a PE ratio of 65.16 and a beta of 1.83. The firm has a 50-day moving average of $18.90 and a 200-day moving average of $15.49. Amphastar Pharmaceuticals Inc. has a 1-year low of $10.50 and a 1-year high of $21.53.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Monday, August 8th. The company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.22. Amphastar Pharmaceuticals had a return on equity of 4.71% and a net margin of 5.19%. The company earned $68 million during the quarter, compared to the consensus estimate of $62.10 million. During the same period in the previous year, the company posted ($0.09) EPS. The firm’s revenue for the quarter was up 26.4% compared to the same quarter last year. Equities analysts expect that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on AMPH shares. Needham & Company LLC upped their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Monday, August 1st. Jefferies Group upped their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. BMO Capital Markets reaffirmed a “hold” rating and issued a $17.00 price objective on shares of Amphastar Pharmaceuticals in a report on Tuesday, August 9th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $23.00 price objective (up previously from $22.00) on shares of Amphastar Pharmaceuticals in a report on Wednesday, September 7th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $20.00.
In other news, Director Richard K. Prins sold 13,993 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $18.03, for a total transaction of $252,293.79. Following the completion of the transaction, the director now directly owns 31,681 shares in the company, valued at approximately $571,208.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William J. Peters sold 2,297 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $17.76, for a total value of $40,794.72. Following the transaction, the chief financial officer now owns 64,652 shares of the company’s stock, valued at $1,148,219.52. The disclosure for this sale can be found here. Insiders own 29.30% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.